Nanthealth stock outlook

NantHealth Reports 2019 Fourth-quarter, Full-year ... Feb 28, 2020 · The MarketWatch News Department was not involved in the creation of the content. NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence … NantHealth Gets FDA Authorization for Omics Core Test | INN

NantHealth, Inc. (NH) Reports Q3 Loss, Misses Revenue ... What's Next for NantHealth, Inc. While NantHealth, Inc. Has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. NantHealth’s Cancer Therapy Pre-Authorization Platform ... NantHealth (NH), a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payers, patients and biopharmaceutical organizations. NantHealth (NH) enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient Nanthealth (NH) Recent Earnings Nanthealth (NH) Recent Earnings. Nanthealth (NH) reported a Quarter December 2019 loss of $0.11 per share on revenue of $24.2 million. on revenue of $23.1 million. Revenue grew 5.8% on a …

May 16, 2018 · Financial results for the 2018 first quarter included approximately $3.3 million loss from related party equity method investment including impairment loss, $2.7 million of stock-based compensation expense, $2.2 million of intangible amortization, and $1.2 million of non-cash interest expense related to convertible notes, totaling $0.09 per share.

NantHealth Reports 2018 First-Quarter Financial Results ... May 16, 2018 · Financial results for the 2018 first quarter included approximately $3.3 million loss from related party equity method investment including impairment loss, $2.7 million of stock-based compensation expense, $2.2 million of intangible amortization, and $1.2 million of non-cash interest expense related to convertible notes, totaling $0.09 per share. NEL:Frankfurt Stock Quote - NantHealth Inc - Bloomberg Markets Stock analysis for NantHealth Inc (NEL:Frankfurt) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Why we chose to invest in NantHealth - CNBC

NantHealth Presents Research Demonstrating Real World ... Dec 11, 2019 · NantHealth (NH), a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payors, patients and biopharmaceutical organizations. NantHealth (NH) enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes.

NantHealth, Inc. (NH) May Report Negative Earnings: Know ...

Find real-time NH - NantHealth Inc stock quotes, company profile, news and forecasts from CNN Business. Find real-time NH - NantHealth Inc stock quotes, company profile, news and forecasts from NantHealth, Inc. (NH) Stock Analysis & News | Seeking Alpha Get breaking news and analysis on NantHealth, Inc. (NH) stock, price quote and chart, trading and investing tools.

NQ) including stock quotes, financial news, historical charts, company background, company fundamentals, company financials, insider trades, annual reports 

NantHealth Gets FDA Authorization for Omics Core Test | INN NantHealth (NASDAQ:NH) has been granted marketing authorization for its Omics Core test from the US Food and Drug Administration (FDA), the company said on Tuesday (November 12). The Omics Core NantHealth, Inc. (NH) Reports Q3 Loss, Misses Revenue ... What's Next for NantHealth, Inc. While NantHealth, Inc. Has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook.

NH - Nanthealth Stock Price - Barchart.com